Vernalis plc (LON:VER) had its target price dropped by stock analysts at Panmure Gordon from GBX 76 ($0.94) to GBX 65 ($0.81) in a research note issued to investors on Thursday. The firm currently has a “buy” rating on the stock. Panmure Gordon’s target price would indicate a potential upside of 95.49% from the stock’s previous close.

A number of other brokerages have also recently issued reports on VER. N+1 Singer restated a “hold” rating and issued a GBX 46 ($0.57) price objective on shares of Vernalis plc in a research note on Thursday, September 29th. Stifel Nicolaus restated a “buy” rating and issued a GBX 99 ($1.23) price objective on shares of Vernalis plc in a research note on Thursday, September 29th. Finally, Canaccord Genuity increased their target price on shares of Vernalis plc from GBX 84 ($1.04) to GBX 88 ($1.09) and gave the stock a “buy” rating in a research report on Thursday, September 29th. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Vernalis plc presently has an average rating of “Buy” and an average target price of GBX 69 ($0.86).

Shares of Vernalis plc (LON:VER) opened at 34.0625 on Thursday. The company’s 50-day moving average is GBX 37.51 and its 200 day moving average is GBX 41.75. The firm’s market capitalization is GBX 179.24 million. Vernalis plc has a 1-year low of GBX 31.00 and a 1-year high of GBX 72.75.

COPYRIGHT VIOLATION NOTICE: “Panmure Gordon Cuts Vernalis plc (VER) Price Target to GBX 65” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this report can be accessed at

In related news, insider Carol Ferguson acquired 28,000 shares of the stock in a transaction on Friday, September 30th. The stock was purchased at an average price of GBX 41 ($0.51) per share, for a total transaction of £11,480 ($14,241.41). Also, insider David Mackney sold 27,233 shares of the firm’s stock in a transaction dated Wednesday, October 12th. The shares were sold at an average price of GBX 39 ($0.48), for a total transaction of £10,620.87 ($13,175.62).

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Receive News & Stock Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related stocks with our FREE daily email newsletter.